Alan Thompson from Royal College London: Rapid Progress Made in Progressive Multiple Sclerosis

Video

Patients diagnosed with relapsing remitting multiple sclerosis have seen their treatment options increase dramatically in recent years. Now patients with the progressive forms are seeing the the start of momentum building in their favor.

Patients diagnosed with relapsing remitting multiple sclerosis have seen their treatment options increase dramatically in recent years. Now patients with the progressive forms are seeing the the start of momentum building in their favor.

Alan Thompson, MD, from University College London, and one of the leaders of the Progressive MS Alliance discussed the latest developments in treatment, including a trio of awards presented by the alliance at the annual ECTRIMS meeting in London. The awards, given to some of the leading minds in the field on international projects are meant to help keep the momentum moving forward and show demonstrable over the next four years and beyond.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.